Abstract. Epigenetic inactivation of GADD45A is a common occurrence in different types of cancer. However, little is known regarding its association with radiosensitivity in cervical cancer (CC). Thus, the present study aimed to investigate the association between aberrant GADD45A methylation and radiosensitivity in CC. SiHa, HeLa and CaSki CC cells were treated with 5-azacytidine (5-azaC), with or without irradiation. The expression levels of GADD45A and AKT related molecules were detected via reverse transcription-quantitative PCR and western blot analyses. The methylation status of GADD45A was assessed via methylation-specific PCR and cell proliferation assays, while clonogenic assays and flow cytometric analysis were performed to assess the function of the genes (GADD45A and AKT) in the CC cell lines. The results demonstrated that methylation of GADD45A was significantly higher in the radioresistant tissues (63.16%) compared with the radiosensitive samples (33.33%). In addition, the surviving fraction of SiHa cells following irradiation with 2 Gy was demonstrated to be highest amongst the three CC cells (CaSki, 57±9.5%; HeLa, 70±4% and SiHa, 75±10%). The survival rate of SiHa cells following treatment with 5-azaC and ionizing radiation (IR) significantly decreased as the radiation dose increased, compared with treatment with IR alone. Following overexpression of GADD45A or treatment with 5-azaC, the radiosensitivity of SiHa cells significantly increased compared with both the control vector and PBS treated groups. In addition, the AKT inhibitor, MK-2206, increased the radiosensitivity of SiHa cells. Notably, aberrant methylation of GADD45A was associated with decreased radiosensitivity in CC, and the PI3K/AKT signaling pathway was essential for radioresistance, which was mediated through downregulation of GADD45A.

Introduction

Despite advancements in the prevention, detection and treatment of diseases during the past decade, cervical cancer (CC) remains the fourth most common malignancy in women worldwide (1). In 2018, the incidence of cervical cancer was 6.6% worldwide (2). Radiotherapy is an effective treatment, particularly for patients with advanced cancer (3). However, patients with advanced stages of CC still suffer from treatment failure due to the development of resistance to radiotherapy (4). Increasing the sensitivity to radiotherapy in patients resistant to it can improve tumor control and decrease the side effects of conventional treatment (5). Technological advancements in radiotherapy, such as intensity-modulated radiotherapy, have contributed to decreased treatment-related toxicity for patients with locally-advanced cancer (6); however, the molecular mechanisms underlying the development of radioresistance, and the associated biomarkers remain unknown. Currently, several
gene variations (7), tumor microenvironmental changes (8), hypoxia (9) and specific signaling pathways (10,11) contribute to cellular resistance against radiotherapy. These factors enhance DNA repair, decrease apoptosis and increase genetic instability (7,12). Thus, it remains critical to investigate the molecular mechanism and prognostic markers of radioresistance, in order to increase effectiveness of radiotherapy.

Recent studies have demonstrated an association between the radiosensitivity of cancer cells and methylation levels (13-15). Epigenetic modifications, particularly promoter hypermethylation, which results in silencing of the expression of tumor suppressor genes, contribute to the regulation of cellular events associated with cancer development and progression, such as apoptosis (16), cell cycle (17), proliferation (18) and DNA repair (19); and the mechanisms above have been identified to have an effect on radiosensitivity (20,21).

Previous studies have reported that hypermethylation of DNA is observed in CC (22-25). Currently, few reports have investigated the association between DNA methylation and radioresistance of CC (26,27). Notably, it has been suggested that the GADD45 gene family act as DNA damage-inducing and growth-inhibiting genes, which function as tumor suppressors for targeted therapy (28). Furthermore, it has been demonstrated that GADD45 induces epigenetic inactivation in different types of cancer and cancer cell lines, including anaplastic thyroid cancer, hepatocellular carcinomas, non-Hodgkin, Hodgkin lymphoma, nasopharyngeal, cervical, esophageal and lung carcinoma (28,29).

However, whether aberrant GADD45A methylation is associated with radiosensitivity in CC remains to be determined. Thus, the present study aimed to investigate the function of GADD45A methylation in CC radiotherapy, and determine its underlying molecular mechanism. Taken together, the results of the present study suggest that aberrant GADD45A methylation is associated with decreased radiosensitivity in CC, which is mediated via the PI3K/AKT signaling pathway.

Materials and methods

Cell culture and treatment. The human SiHa, CaSki and HeLa CC cell lines were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences. CC cells were plated into 60 mm culture dishes at a density of 6×10^3 cells/well and maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% ampicillin and streptomycin (all purchased from Gibco; Thermo Fisher Scientific, Inc.), at 37˚C with 5% CO_2.

Cells were subsequently treated with 5-azacytidine (5-azaC; Sigma-Aldrich; Merck KGaA) and/or irradiated with 3.6 Gy/min at room temperature using an X-Rad 225 X-ray generator (Precision X-ray Inc., https://precisionxray.com/x-rad/small-animal-irradiator/). The experimental groups were as follows: 5-azaC group (0, 1, 3, 5 or 10 µmol/l for 24, 48 and 72 h); ionizing radiation (IR) group (0, 2, 4, 6, 8 or 10 Gy) or IR and 5-azaC/IR-2206. Following treatment, cells were digested, collected via centrifugation (1,000 x g for 5 min at room temperature), diluted and seeded into 6-well plates at different cell densities (100 cells for control, 200 cells for 2 Gy, 800 cells for 4 Gy, 1,800 cells for 6 Gy, 3,000 cells for 8 Gy and 5,000 cells for 10 Gy). After 10-15 days, the cells were fixed in methanol for 15 min and stained with trypan blue solution for 20 min at room temperature, and the number of cell colonies per dish were counted with the naked eye. Colonies containing at least 50 cells were counted. Cell survival curves were constructed using a multi-target single-hit model: S(D)=1−(1−e^{−D/D_0}); where D is the single dose fraction, and D0 is defined as the given average hit dose per target. The number of sensitive targets in a cell was denoted by n (30). The survival fraction (SF) was determined from the number of colonies formed after treatment relative to the colony counts with the plating efficiency of the non-irradiated cells.

Methylation-specific PCR (MSP). Genomic DNA was extracted from CC cells (5x10^5) using a DNA Extraction kit (cat. no. K180001; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. To assess the DNA methylation patterns, an EpiTect® Bisulfite kit (cat. no. 59110; Qiagen, Inc.) was used to perform the sodium bisulfite modification. The primer sequences and annealing temperatures were used as previously described (31). The amplified products were analyzed on 3% agarose gels, stained with ethidium bromide (Thermo Fisher Scientific, Inc.) for 15 min at room temperature and visualized under a UV light.

Reverse transcription-quantitative (RT-q)PCR analysis. Total cellular RNA was extracted using RNAiso Plus (Takara Bio, Inc.). Agarose gel analysis was performed to assess the quality of RNA. cDNA was produced from 1 µg total RNA using the RT Reagent kit (cat. no. RR037A, Takara Bio, Inc.), according to the manufacturer's protocol.

Cell Counting Kit-8 (CCK-8) assay. SiHa CC cells were seeded into 96-well plates at a density of 3x10^3 and treated with 5-azaC (1, 3, 5 or 10 µmol/l) after 24 h. The CCK-8 assay (Dojindo Molecular Technologies, Inc.) was performed after 24, 48 and 72 h of 5-azaC treatment, and viability was subsequently analyzed at a wavelength of 450 nm using a microplate reader (Thermo Fisher Scientific, Inc.). Cell viability was assessed using the following formula: Cell viability (%) = [(As-Ab)/(Ac-Ab)] x100; where As = absorbance of the experimental well, Ab = blank well absorbance and Ac = control well absorbance.

Clonogenic assay. Cells were seeded into 60 mm dishes at a density of 6x10^3 cells/well and treated with 5-azaC alone (0 or 5 µmol/l) for 72 h or MK-2206 (0 or 0.5 µmol/l) for 48 h, IR alone (0, 2, 4, 6, 8 or 10 Gy) or IR and 5-azaC/IR-2206. Following treatment, cells were digested, collected via centrifugation (1,000 x g for 5 min at room temperature), diluted and seeded into 6-well plates at different cell densities (100 cells for control, 200 cells for 2 Gy, 800 cells for 4 Gy, 1,800 cells for 6 Gy, 3,000 cells for 8 Gy and 5,000 cells for 10 Gy). After 10-15 days, the cells were fixed in methanol for 15 min and stained with trypan blue solution for 20 min at room temperature, and the number of cell colonies per dish were counted with the naked eye. Colonies containing at least 50 cells were counted. Cell survival curves were constructed using a multi-target single-hit model: S(D)=1−(1−e^{−D/D_0}); where D is the single dose fraction, and D0 is defined as the given average hit dose per target. The number of sensitive targets in a cell was denoted by n (30). The survival fraction (SF) was determined from the number of colonies formed after treatment relative to the colony counts with the plating efficiency of the non-irradiated cells.
expression levels were quantified using the 2^{-ΔΔCq} method (32) and normalized to the internal reference gene GAPDH.

**Western blotting.** SiHa CC cells were homogenized on ice using RIPA lysis buffer (Beyotime Institute of Biotechnology), and centrifuged at 1,200 x g for 5 min at 4˚C. The supernatant was collected and stored at -80˚C until subsequent experimentation.

Protein concentrations were determined using a BCA Protein assay kit (cat. no. 7780, Cell Signaling Technology, Inc.) and ~40 µg protein/lane was separated via SDS-PAGE on a 10% gel at 120 V constant voltage. The separated proteins were subsequently transferred onto PVDF membranes (EMD Millipore) and blocked with 5% non-fat dry milk (cat. no. 9999, Cell Signaling Technology, Inc.) in PBS with 0.1% Tween-20 for 2 h at room temperature. The membranes were incubated with primary antibodies against GADD45A (1:1,000; cat. no. 4632), AKT (1:1,000; cat. no. 4685), p-AKT (Ser 473) (1:2,000; cat. no. 4060) and GAPDH (1:1,000; cat. no. 5174), overnight at 4˚C. All primary antibodies were purchased from Cell Signaling Technology, Inc. Membranes were washed three times with 0.1% TBST, and subsequently incubated with goat anti-rabbit secondary antibody (1:2,000; cat. no. 7074; Cell Signaling Technology, Inc.) at room temperature for 2 h. Protein bands were visualized using SignalFire™ ECL reagent (cat. no. 68683; Cell Signaling Technology, Inc.).

**Cell transfection.** GFP-GADD45A-expression plasmid (GFP-GADD45A), negative control (GFP-NC) and a constitutively active Akt1-expression plasmid (pT3-myr-AKT-HA) were purchased from Shanghai GenePharma Co., Ltd. and Zhongyuan (https://www.tianyancha.com/brand/b44b6550128), respectively. Briefly, 1 day prior to transfection, SiHa cells were seeded into 60 mm culture dishes at a density of 3x10^6 cells per dish and allowed to reach 80% confluence. A total of 4 µg plasmid and protopodium iodide (cat. no. P1304MP) for 48 h at room temperature, where the drug was added every 24 h. Cells were washed three times with PBS, and flow cytometric analysis was performed to assess cell cycle distribution. Briefly, when cells reached 70% confluence, they were fixed with 70% ethanol overnight at 4˚C. Cells were rehydrated in 5 ml PBS at room temperature for 15 min, collected via centrifugation (at 400 x g for 5 min at room temperature) and resuspended in staining buffer supplemented with 3 µmol/l propidium iodide (cat. no. P1304MP, Thermo Fisher Scientific, Inc.) at room temperature for 30 min. Cells were subsequently incubated with staining buffer for 15 min at room temperature, and cell cycle analysis was performed using a FACScan flow cytometer (Beckman Coulter, Inc.) and CellQuest software version 4.0 (Becton Dickinson).

**Tissue samples and grouping criteria.** A total of 59 patients with International Federation of Gynecology and Obstetrics 2009 (33) stages IIB-IIIB CC, histologically diagnosed with squamous CC and treated at the Attired Tumor Hospital of Guangxi Medical University between September 2015 and June 2016 were enrolled in the present study. The median age of the patients was 45.8 years (age range, 27-74 years). CC tissues were collected from patients who had not received chemotherapy prior to radiation therapy. Patients with standard radiotherapy received concurrent weekly cisplatin (40 mg/m²).

Radioresistant and radiosensitive patients were assessed 6 months after completion of radiation therapy via coloscopically directed biopsy. Patients were considered radiosensitive if the lesions completely subsided at the end of radiotherapy and the tumor could not be observed in the cervix at the 6-month follow-up. Patients were considered radioresistant if there was still a residual tumor visible to the naked eye following completion of radiotherapy, which was confirmed by biopsy in the cervix or the presence of tumor tissue confirmed by cervical biopsy at the 6-month follow-up.

The present study was approved by the Research Ethics Committee of Guangxi Medical University (Guangxi, China; approval no. LW2020063), and written informed consent was provided by all participants prior to the study start.

**Statistical analysis.** Statistical analysis was performed using SPSS version 24.0 (SPSS Inc.). In vitro experiments were performed in triplicate and data are presented as the mean ± standard deviation. Unpaired Student's t-test was used to compare differences between two independent groups, while one-way analysis of variance, followed by Tukey's post hoc test were performed to compare differences between multiple groups. The χ² test was used to compare the effect of GADD45A hypermethylation on radiosensitivity in patients with CC. P<0.05 was considered to indicate a statistically significant difference.

**Results**

Promoter methylation of GADD45A in primary CCs and their association with radioresistance. All 59 CC tissue samples were assessed via MSP, and the results demonstrated the possibility of three states: Methylation, incomplete methylation and
no methylation (Fig. 1). When incomplete methylation was included into the methylation status for statistical analysis, the results demonstrated that methylation of GADD45A was significantly higher in the radioresistant tissues (63.16%) compared with the radiosensitive samples (33.33%) (P<0.05; Table I). GADD45A promoter methylation in the remaining patients with CC is presented in Fig. S1.

**Table I. Association between GADD45A hypermethylation and radiosensitivity in cervical cancer tissues.**

<table>
<thead>
<tr>
<th>Tumor status</th>
<th>GADD45A hypermethylation</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiosensitive</td>
<td>33.33% (7/21)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Radioresistant</td>
<td>63.16% (24/38)</td>
<td></td>
</tr>
</tbody>
</table>

Differential GADD45A CpG methylation status, and protein and mRNA levels in the three CC cell lines with different tolerances to radiotherapy. Radiosensitivity was assessed by comparing the SF values in cells treated with 2 Gy irradiation (SF2). As presented in Fig. 2A, the SF2 value of SiHa cells was the highest amongst the three CC cells (CaSki, 57±9.5%; HeLa, 70±4% and SiHa, 75±10%). Consistent with previous findings, the results of the present study demonstrated that SiHa cells exhibited low sensitivity to irradiation, as they had significantly higher SF2 values compared with the other two CC cell lines (P<0.05).

RT-qPCR and western blot analyses were performed to detect GADD45A mRNA (Fig. 2B) and protein expression levels (Fig. 2C), respectively. Notably, GADD45A mRNA and protein expression levels were lower in SiHa cells compared with the other two CC cell lines.

MSP analysis was performed to determine whether there was an association between the methylation status of GADD45A and downregulation of GADD45A (Fig. 2D). Methylation of GADD45A was evident in SiHa cells; however, a negative association was observed between the methylation status and expression of GADD45A.

**Figure 2. Differential GADD45A methylation status and radiosensitivity of the three CC cell lines. (A) Radiosensitivity was assessed in CaSki, HeLa and SiHa cells, and determined via a colony formation assay, by measuring the cells as the survival fraction following treatment with 2 Gy radiation. High GADD45A (B) mRNA and (C) protein expression levels were associated with cellular sensitivity to radiation in CC cells. (D) Aberrant methylation of the GADD45A promoter was associated with decreased radiosensitivity in CC cells. *P<0.05, ***P<0.001. CC, cervical cancer; NS, not significant; M, methylated; U, unmethylated.**

**Effects of the DNA methylation inhibitor, 5-azaC, on the viability of SiHa cells and the role of GADD45A.** Based on the aforementioned results, SiHa cells were selected for subsequent experimentation. SiHa cells were incubated with 0, 1, 3, 5, or 10 µmol/l 5-azaC to assess the cytotoxic effects of 5-azaC. Cell viability was assessed via the CCK-8 assay following treatment with different concentrations of 5-azaC treatment for 24, 48 and 72 h. As presented in Fig. 3A, no statistically significant differences were observed between treatment with the different concentrations of 5-azaC (P>0.05).

Notably, GADD45A mRNA and protein expression levels significantly increased in SiHa cells following treatment with 5 or 10 µmol/l 5-azaC for 72 h (Fig. 3B and C).

5-azaC decreases radioresistance of SiHa cells in vitro. To determine whether the demethylating agent decreased the radioresistance of SiHa cells, the survival fraction of SiHa
cells was assessed via the colony formation assay following treatment with 5 µmol/l 5-azaC. The survival fraction of SiHa cells treated with 5-azaC and IR significantly decreased in a dose-dependent manner compared with IR treatment alone (P<0.05; Fig. 4).

Overexpression of GADD45A increases the radiosensitivity of SiHa cells in vitro. To assess the effect of GADD45A on the radiosensitivity of CC cells, GADD45A was overexpressed in SiHa cells using a GFP-GADD45 expression plasmid. RT-qPCR analysis was performed to detect GADD45A mRNA expression levels (Fig. 5A). The clonogenic assay was performed to assess the effect of GADD45A on the sensitivity of SiHa cells to irradiation. As presented in Fig. 5B, overexpression of GADD45A or treatment with the demethylating agent significantly increased the radiosensitivity of SiHa cells compared with the Vec and PBS treated groups, respectively (P<0.05).

PI3K/AKT signaling is required for radioresistance, which is mediated by downregulation of GADD45A. To determine the underlying molecular mechanism of GADD45A-related regulation on the radiosensitivity of CC cells, SiHa cells were transfected with GADD45A and/or AKT DNA. Western blot analysis was performed to detect GADD45A and AKT protein expression levels in SiHa cells. The results demonstrated that co-transfection with GADD45A and AKT reversed the effects of GADD45A overexpression (Fig. 5A). The levels of phosphorylated AKT significantly decreased in a dose-dependent manner following treatment with different concentrations of MK-2206 (0, 0.1, 0.2 and 0.5 µmol/l) for 48 h. In addition, phosphorylation of AKT protein at Ser 473 decreased, whereas total AKT protein levels were not significantly altered (Fig. 6B). The colony formation assay was performed to assess the radiosensitivity of SiHa cells treated with 0.5 µmol/l MK-2206. The results demonstrated that MK-2206 enhanced the radiosensitivity of SiHa CC cells compared with the untreated cells (Fig. 6C). In addition, flow cytometric analysis demonstrated that MK-2206 did not significantly alter the proportion of cells in the different phases of the cell cycle (P>0.05; Fig. 6D). Taken together, these results suggest that the PI3K/AKT signaling pathway is essential for radiosensitivity, which is mediated by GADD45A downregulation; however, it is not associated with cell cycle distribution.
Discussion

5-azaC is a well-known DNA methyltransferase inhibitor, which induces DNA hypomethylation and epigenetic silencing of gene expression (34). The results of the present study demonstrated that application of a demethylation reagent (5 µmol/l 5-azaC) regulated GADD45A expression. Notably, 5 µmol/l 5-azaC did not exhibit substantial cytotoxic...
effects in the three CC lines. Furthermore, in vitro experiments indicated that the colony formation ability of SiHa cells was further inhibited by a combination of 5-azaC and IR, compared with IR alone.

Based on current literature, GADD45 family members appear to be infrequently mutated in cancer; however, decreased expression levels of GADD45 family members, due to DNA methylation, have been frequently reported in several types of cancer, including gastric, colorectal and pancreatic cancers (35). The results of the present study demonstrated that GADD45A hypermethylation was significantly higher in the radiotherapy resistance tissues (63.16%) compared with the radiotherapy sensitive tissues (33.33%). Similar results were observed at the cellular level. The GADD45A promoter was completely methylated in SiHa cells, but unmethylated in CaSki cells. Notably, the majority of epigenetic studies in cancer have focused on the methylation of tumor suppressor gene promoters in cell lines, demonstrating different sensitivities (36-38). For example, Kim et al (39) reported that aberrant methylation of ataxia telangiectasia mutated (ATM) is associated with decreased radioresistance in a colorectal cell line, HCT-116.

Based on the effective radiosensitization of 5-azaC, the underlying molecular mechanism was further assessed in SiHa cells. Apoptosis is one of the most common causes of radioresistance (40). In the present study, 10 µmol/l 5-azaC failed to induce substantial cytotoxicity in unirradiated SiHa cells. However, 5-azaC induced a significant increase in apoptosis during irradiation. In addition, re-expression of GADD45A following treatment with 5-azaC increased the radiosensitivity of SiHa cells. The results demonstrated that the AKT inhibitor, MK-2206, enhanced the radiosensitivity of SiHa cells. It has been reported that the AKT signaling pathway promotes resistance to chemotherapy, radiotherapy and targeted therapy in different types of cancer, including colorectal cancer (41), non-small cell lung cancer (42), ovarian cancer (43) and glioma cell lines (44). Thus, it was hypothesized that downregulation of GADD45A decreases inactivation of the PI3K/AKT signaling pathway, and contributes to cellular resistance against radiotherapy.

Cell cycle arrest is a common cause of increased radioresensitivity (45). In the present study, pretreatment with 5 µmol/l 5-azaC did not impact the cell cycle of SiHa cells. These results are consistent with studies on colorectal cancer (46), nasopharyngeal carcinoma (47), lung cancer (48) and glioblastoma cell lines (49). However, SiHa cells treated with 10 µmol/l 5-azaC remained in the G0/M phase in CC cells (unpublished data). Similar results have been reported following treatment with demethylating agents in breast cancer (50) and endometrial carcinoma (51). The reason for this discrepancy may be due to the different types of cell lines or the different concentrations of demethylating agents used.

In conclusion, the results of the present study demonstrated that hypermethylation of GADD45A was observed in patients with CC, with decreased radiosensitivity, and the PI3K/AKT signaling pathway was required for radioresistance due to downregulation of GADD45A in CC. Taken together, these results suggest that clinical application of epigenetic regulators may be a promising avenue to increase the radiosensitivity of CC.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

Authors' contributions
ML, QZ, and LL designed the present study. ML and LYZ performed the experiments. ML, RL, and TYL analyzed the data. ML and RL drafted the initial manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
The present study was approved by The Research Ethics Committee of Guangxi Medical University (Guangxi, China; approval no. LW20200063), and written informed consent was provided by all participants prior to the study start.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.